Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ACRV Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 09, 2026
Report Source: 2026 1st Quarter Report
Acrivon Therapeutics Inc. Stock Analysis ACRV
United States Health Care Micro Cap Report: Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Read More Acrivon Therapeutics Inc (ACRV) Chart
Key Statistics of Acrivon Therapeutics Inc (ACRV)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.56Volume
350.36KP/E Ratio (TTM)
-52 Week Range
Market Cap
76.62MAvg. Volume
367.52KDividend Yield
-Financial Metrics & Statements of Acrivon Therapeutics Inc (ACRV)
FAQ's for Acrivon Therapeutics Inc (ACRV)
- According to Musaffa’s Shariah screening methodology, Acrivon Therapeutics Inc (ACRV) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Acrivon Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Acrivon Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Acrivon Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Acrivon Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Acrivon Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.